Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

Abstract

In the present study, we investigated the effects of sertraline on plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and serum brain-derived neurotrophic factor (BDNF) levels in 59 depressed patients treated with sertraline. We also examined the relationship between the dynamics of the catecholamine metabolites, BDNF, serotonin transporter-linked polymorphic region (5-HTTLPR) gene polymorphism (long and short alleles), and the clinical response to sertraline. The extent of clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (Ham-D) before and 8 weeks after treatment with sertraline. Responders were defined as showing at least a 50% decrease in the Ham-D score. Baseline plasma HVA levels of responders to sertraline treatment were significantly lower than those of non-responders (p = 0.02). In addition, a positive correlation was identified between changes in plasma HVA levels and the rate of response to sertraline treatment (p = 0.001). A trend toward higher baseline serum BDNF levels was found in responders compared with non-responders (p = 0.095). In addition, serum BDNF levels were slightly increased (not significant) in responders (p = 0.058), but not in non-responders. Responders had a higher short-allele genotype frequency in the 5-HTTLPR for the promoter region than did non-responders (p = 0.037). These results suggest that pre-treatment plasma HVA levels and the 5-HTTLPR genotype for the promoter might be associated with a response to sertraline.

Keywords

BDNF MHPG HVA sertraline biological marker 5-HTTLPR depression

Get full access to this article

View all access options for this article.

References

Bolden-Watson C. , Richelson E. ( 1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023-1029.

Demyttenaere K. , De Fruyt J. , Stahl SM ( 2005) The many faces of fatigue in major depressive disorder . Int J Neuropsychop 8: 93-105.

Figurov A. , Pozzo-Miller LD , Olafsson P. , Wang T. , Lu B. ( 1996) Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381: 706-709.

Gelernter J. , Kranzler H. , Cubells JF ( 1997) Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101: 243-246.

Hamilton M. ( 1967) Development of a rating scale for primary depressive illness . Brit J Soc Clin Psyc 6: 278-296.

Heils A. , Teufel A. , Petri S. , et al. (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.

Hori H. , Yoshimura R. , Yamada Y. , et al. (2007) Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharm 22: 21-27.

Kato M. , Ikenaga Y. , Wakeno M. , et al. (2005) Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism . Int Clin Psychopharm 20: 151-156.

Kirchheiner J. , Nickchen K. , Sasse J. , Bauer M. , Roots I. , Brockmoller J. ( 2007) A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 7: 48-55.

10.

Kopin IJ ( 1985) Catecholamine metabolism: basic aspects and clinical significance . Pharmacolo Rev 37: 333-364.

11.

Kunugi H. , Hattori M. , Kato T. , et al. (1997) Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder . Mol Psychiatr 2: 457-462.

12.

Lesch KP , Bengel D. , Heils A. , et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.

13.

Mandrioli R. , Saracino MA , Ferrari S. , Berardi D. , Kenndler E. , Raggi MA ( 2006) HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. J Chromatogr. B, Analytical Technologies in the Biomedical and Life Sciences 836: 116-119.

14.

Mauri MC , Fiorentini A. , Cerveri G. , et al. (2003) Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Human Psychopharmacology 18: 385-388.

15.

Minegishi A. , Ishizaki T. ( 1984) Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 311: 51-57.

16.

Montgomery SA , Asberg M. ( 1979) A new depression scale designed to be sensitive to change . Brit J Psychiat 134: 382-389.

17.

Nagaoka S. , Iwamoto N. , Arai H. ( 1997) First-episode neuroleptic-free schizophrenics: concentrations with clinical response to haloperidol treatment. Biol Psychiat 41: 857-864.

18.

Nutt DJ ( 2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiat 69: 4-7.

19.

Rapoport MJ , Chan F. , Lanctot K. , Herrmann M. , McCullagh S. , Feinstein A. ( 2008) An open-label study of citalopram for major depression following traumatic brain injury. J Psychopharmacol 22: 860-864.

20.

Salamone JD , Correa M. , Mingote S. , Weber SM ( 2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305: 1-8.

21.

Schmitt JA , Ramaekers JG , Kruizinga MJ , van Boxtel MP , Vuurman EF , Riedel WJ ( 2002) Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 16: 207-214.

22.

Sen S. , Duman R. , Sanacora G. ( 2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiat.

23.

Serretti A. , Kato M. , De Ronchi D. , Kinoshita T. ( 2007) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiat 12: 247-257.

24.

Shinkai K. , Yoshimura R. , Ueda N. , Okamoto K. , Nakamura J. ( 2004) Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharm 24: 11-17.

25.

Stahl SM ( 2008) Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series), Third ed. Cambridge: Cambridge University Press.

26.

Tatsumi M. , Groshan K. , Blakely RD , Richelson E. ( 1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eu J Pharmacol 340: 249-258.

27.

Ueda N. , Yoshimura R. , Shinkai K. , Nakamura J. ( 2002) Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35: 175-181.

28.

Yeung PK , Buckley SJ , Pedder SC , Dingemanse J. ( 1996) Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85: 451-453.

29.

Yoshida K. , Ito K. , Sato K. , et al. (2002) Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 26: 383-386.

30.

Yoshimura R. , Mitoma M. , Sugita A. , et al. (2007) Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychoph 31: 1034-1037.

31.

Yoshimura R. , Nakamura J. , Shinkai K. , et al. (2004) Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychoph 28: 611-616.

32.

Yoshimura R. , Nakamura J. , Ueda N. , Terao T. ( 2000) Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement . Int Clin Psychopharm 15: 175-180.